Fridge-free tetanus-diphtheria vaccine succeeds in first human trial
Phase 1 results show SPVX02 remains effective after two years at 30°C, with no serious side effects
AI-assisted coverage comparison, editor-supervised · How this was made
Fridge-free tetanus-diphtheria vaccine succeeds in first human trial
Photograph: Medical Xpress (embedded from source)
What this story says
- The phase 1 trial of SPVX02, a fridge-free tetanus-diphtheria vaccine, enrolled 60 healthy adults in the UK.
- All participants achieved protective antibody levels against tetanus and diphtheria by day 28, with no vaccine-related serious adverse events reported.
- The vaccine remained stable and fully potent after storage at up to 30°C for at least two years, according to the study published in *eClinicalMedicine*.
- A phase 2b trial is now underway to further assess the vaccine in a larger group of participants.
Who covered it
Percentages are shares of the 4 outlets carrying a published leaning rating. 7 of the 11 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .
Trust
86/100
Craft
80/100
Hype
18/100
11 sources · methodology
A tetanus-diphtheria vaccine that does not require refrigeration has shown promising results in its first human trial. The vaccine, SPVX02, was developed by UK-based biotech company Stablepharma using its StablevaX technology. It is a reformulated version of a licensed vaccine, designed to remain stable at temperatures up to 30°C for at least two years.
The phase 1 trial, led by the University of Southampton and University Hospital Southampton NHS Foundation Trust, enrolled 60 healthy adults. By day 28 after vaccination, all participants who received SPVX02 achieved protective antibody levels against both tetanus and diphtheria. The study, published in *eClinicalMedicine*, reported no vaccine-related serious adverse events. The vaccine also remained stable after three cycles of extreme temperature fluctuations between -20°C and +40°C.
The World Health Organization has previously stated that a significant portion of vaccines are wasted globally each year due to temperature changes during storage and transport. The trial’s findings suggest that fridge-free vaccines could reduce this waste and improve access in remote or conflict-affected regions where maintaining a cold chain is difficult.
What the coverage left out
No left- or right-rated outlet ran this story. The omission is a finding: the story was covered exclusively by centre-rated and unrated outlets. None of the digests or reports specified the exact percentage of vaccines wasted globally, though the World Health Organization’s estimate was referenced in the full reports from Medical Xpress and EIN Presswire.
Coverage settled. We checked this 341 times and stopped on 12 Aug 2026, 10:00. The figures above are what it finished at.
How each side covered it
Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.
Left
0 rated outlets
No outlet rated left ran this story. We watched the coverage until it stopped changing, and none appeared.
Centre
4 rated outlets
- The three centre-rated reports, Medical Xpress, *The BMJ*, and BBC News, led on the vaccine’s potential to address cold-chain failures and improve global access. Medical Xpress quoted Professor Saul Faust, who led the trial, saying the vaccine could "transform the way vaccines are stored and delivered around the world" if larger studies confirm the findings. *The BMJ* described the development as a potential "game changer" for global health, particularly in resource-poor settings.
- BBC News focused on the broader implications, framing the trial as a solution to vaccine wastage. None of the centre-rated digests mentioned the specific percentage of vaccines wasted globally, though Medical Xpress and *The BMJ* referenced the issue in general terms. All three reports highlighted the vaccine’s stability at 30°C and its potential to reduce reliance on refrigeration.
Right
0 rated outlets
No outlet rated right ran this story. We watched the coverage until it stopped changing, and none appeared.
Questions about this coverage
- How did the left and right cover Fridge-free tetanus-diphtheria vaccine succeeds in first human trial?
- Of the 4 outlets on this story carrying a published leaning rating, 0% are rated left, 100% are rated centre, 0% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 11. The sections above set out what each side emphasised, in its own terms.
- Is Fridge-free tetanus-diphtheria vaccine succeeds in first human trial left or right?
- Too few of the outlets on this story carry a published leaning rating to say. 4 of them do, and this site does not characterise a field under 12: at that size one newsroom filing moves the share by ten points. The percentages above are the count as it stands.
- Is the coverage of Fridge-free tetanus-diphtheria vaccine succeeds in first human trial biased?
- Fridge-free tetanus-diphtheria vaccine succeeds in first human trial is one event reported by 11 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
- Which outlets covered Fridge-free tetanus-diphtheria vaccine succeeds in first human trial?
- 11 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
- What is SPVX02?
- SPVX02 is a fridge-free tetanus-diphtheria vaccine developed by UK-based biotech company Stablepharma. It is designed to remain stable at temperatures up to 30°C for at least two years, addressing cold-chain failures that lead to vaccine wastage globally.
- What were the results of the phase 1 trial?
- The phase 1 trial enrolled 60 healthy adults and found that all participants achieved protective antibody levels against tetanus and diphtheria by day 28. No vaccine-related serious adverse events were reported, and the vaccine remained stable after storage at 30°C for two years.
- Why is a fridge-free vaccine significant?
- A fridge-free vaccine could reduce vaccine wastage caused by temperature changes during storage and transport. It could also improve access in remote or conflict-affected regions where maintaining a cold chain is difficult, potentially saving millions of doses annually.
Read it at the source
11 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.
Left
0No outlet in this group ran the story.
Centre
4- Vaccines that Don't Require Refrigeration: an Innovation that Could Reduce the Waste of Half of All Vaccines Globally (opens cedarnews.net in a new tab)
cedarnews.net — is cedarnews.net biased? Our profile of this outlet
- Fridge-free tetanus-diphtheria vaccine shows promise of reaching millions worldwide (opens Medical Xpress in a new tab)
Medical Xpress — is Medical Xpress biased? Our profile of this outlet
- “Fridge-free” vaccine for tetanus-diphtheria shows promise in first human trial (opens The BMJ in a new tab)
- Half of vaccines are binned - this plant could change that (opens BBC News in a new tab)
Right
0No outlet in this group ran the story.
Not rated
7- Successful Trials of Fridge-Free Vaccines To Boost Global Distribution (opens European Medical Journal in a new tab)
European Medical Journal — is European Medical Journal biased? Our profile of this outlet
- Fridge-free vaccine shows promise for reaching millions more people worldwide (opens nihr.ac.uk in a new tab)
nihr.ac.uk — is nihr.ac.uk biased? Our profile of this outlet
- Safety, tolerability, and immunogenicity of SPVX02, a room temperature-stabilised tetanus-diphtheria vaccine, compared to two established tetanus-diphtheria booster vaccines: a multicentre, single-blind, randomised, first-in-human phase 1 trial in the UK (opens The Lancet in a new tab)
The Lancet — is The Lancet biased? Our profile of this outlet
- Fridge-free vaccine trial shows ‘encouraging results’ (opens nursinginpractice.com in a new tab)
nursinginpractice.com
- Fridge-free vaccine shows promise for reaching millions more people worldwide (opens uhs.nhs.uk in a new tab)
uhs.nhs.uk — is uhs.nhs.uk biased? Our profile of this outlet
- Phase 1 results from ‘fridge-free’ tetanus-diphtheria vaccine (opens Science Media Centre in a new tab)
Science Media Centre — is Science Media Centre biased? Our profile of this outlet
- The Lancet’s eClinicalMedicine Publishes Phase I Data for SPVX02, a Fridge-free Td Vaccine Stable for 24 Months at 30°C (opens EIN Presswire in a new tab)
EIN Presswire — is EIN Presswire biased? Our profile of this outlet
How did this read?
About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.
More in Science & Tech
All Science & Tech →
Elsewhere on the site
Conflict & Security•2 min readUK Prime Minister Andy Burnham to announce AI defence partnership with US
Business & Economy•3 min readJohn Swinney announces £500m Edinburgh Airport investment
Climate•3 min readScottish dairy sends milk south amid UK drought
Conflict & Security•3 min readTwo injured in incident outside Belleville synagogue